Your New Biotechnology Profile (PRVCF) Displays Over 200% Potential Upside To Recent Highs
Could PRVCF's Next Major Press Release Lead This Company On A Huge Breakout?
With the biotech sector producing several breakout profiles in recent months, I've made it a major focus of mine to locate under-the-radar companies exhibiting major upside potential.
One major biotech idea I delivered to you recently was JanOne Inc. (JAN), a profile that went on a major short-term tear.
Alerted at approximately $5.80 on August 20th, it rushed to a 52-week high of $9.10 on August 26th.
During the short stretch where it made an approximate 56% run, JAN dropped 2 major press releases that stirred up significant buzz and provided it with breakout catalyst fuel.
As I mentioned above, I've been eyeing the markets and looking for a new biotech profile and have come across one that has been releasing major news that may have gone unnoticed to this moment...
For Wednesday, September 9th, this is the biotech profile you need at the top of your watch-list:
PreveCeutical Medical Inc. (PRVCF)
PreveCeutical Medical Inc. develops options for preventive and curative therapies utilizing organic and nature identical products in the United States and Canada.
Headquartered in Vancouver, British Columbia, PreveCeutical Medical Inc. has a world class team with a passion for researching and developing innovative solutions for unmet clinical needs. Bringing to market treatments and therapies that make real, palpable differences in the lives of those who need them. The company is staking out important positions in diverse areas such as diabetes and obesity, pain management, neurological disorders and cancer.
PRVCF May Be Sitting On A Much-Needed Treatment For The Global Pandemic
The world is in desperate need for treatment -- anything to halt the spread.
Hundreds of thousands of people are being infected by the day. Thousands have died. There’s even fear global economies may need to be shut down again. (Source 1 and 2)
The good news is we may be nearing a possible solution.
One that’s quickly creating a multi-Bn-dollar market opportunity for under the radar companies, like PreveCeutical Medical Inc. PRVCF).
After all, the virus is still here – and it’s only getting worse.
Johns Hopkins University is warning of another severe breakout.
"There is a new wave coming in parts of the country," Eric Toner, a senior scholar for Health Security said, as quoted by Bloomberg. "It’s small and it’s distant so far, but it’s coming." (Source 3)
The U.S., China, India, Russia, and Korea are seeing higher numbers.
Worse, we’re “on the cusp of losing control” of the situation, says former US FDA Commissioner, Dr. Scott Gottlieb. (Source 4)
Even the World Health Organization just said the “pandemic is still accelerating.” (Source 5)
We may be nearing a potential treatment from companies like PreveCeutical Medical Inc.
The company just announced that it is preparing for clinical trials for its Sol-Gel CV-19 program. PreveCeutical believes that the canna*binoid ("CBnoid") Sol-gel may reduce the possibility of contracting CV-19 infections.
Your No. 1 Potential Catalyst For PRVCF
PreveCeutical Files an Application for a Provisional Patent for Sol-gel CBnoids
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on August 31, 2020, entitled "CBnoid Formulations and Methods of Use", application number 2020903103, in order to protect sol-gel formulations containing CBnoids for nasal delivery.
The patent also covers CBnoid formulations with respect to sat*iva, ind*ica, hybrid combination, and hemp plants. The patent also refers to both single CBnoid formulations or multiple CBnoid formulations.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "The CBnoid sol-gel formulation is extremely valuable to PreveCeutical's pipeline of intellectual property. With the successful completion of the initial research CBnoid sol-gel program and this provisional patent application, we are continuing to develop the cBnoid sol-gel technology as a product to help prevent and treat CV-19 infections."
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the CV-19 (or SARS-2 C-virus) at this time.
Your No. 2 Potential Catalyst For PRVCF
PreveCeutical Provides Lead Pain Management Peptides Update
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update to its non-addictive analgesic program ("Analgesic Program").
Further to the news release of September 2, 2020, the Analgesic Program consisted of an iterative approach to peptide design resulting in a number of second-generation peptide analogues optimized from the most promising first-generation series. Cell and stability testing results correlate well with the pilot animal studies. The peptides demonstrated analgesic activity in a rodent inflammatory pain model at relatively low doses, with the effects lasting for up to two hours. The results further show that the peptides did not affect inflammation in the pain model, suggesting their effects were associated with an opioid-like analgesic effect.
The Company is very pleased with these results and is currently conducting Pharmacokinetic (PK) studies on select lead peptides. The results of this work will be provided shortly.
PreveCeutical's Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, "We are looking forward to the results of the PK studies. This brings us closer to finding non-addictive pain therapies. We will be investigating patenting the lead peptides once the study is completed. The Company is looking forward to adding this to our pipeline of intellectual property."
Your No. 3 Potential Catalyst For PRVCF
PreveCeutical Announces Lead Pain Management Peptides Identified for Preclinical Evaluation
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update to its non-addictive analgesic program ("Analgesic Program").
The Analgesic Program started in July 2018 to discover and develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation. This discovery program, which utilizes a proprietary disulfide linker technology, is in its final steps of completion. Several promising lead peptides have been identified, which have been shown to be stable in two independent stability assays and shown to be selective for the opioid receptor of interest.
Select peptides from both the linear and cyclized versions have been found to be highly potent when screened in a cell inhibition assay. The lead peptides have been progressed to an evaluation in an inflammatory pain model, and the outcome from those studies will be reported in short order.
PreveCeutical's Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, "We are very pleased with the promising results from research. We are now looking to transition these promising developments to the selection of lead drug candidates for further studies ahead of future clinical trials and commercialization. To address the current global opioid crises, we will seek fast track approval from various regulatory health organizations."
Your No. 4 Potential Catalyst For PRVCF
PreveCeutical Receives AU$1,227,902 Research & Development Tax Incentive Cash Refund
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received AU$1,227,902 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2019. The R&D activities were across PreveCeutival's portfolio, including the Sol-gel nose-to-brain drug delivery system and the non-addictive analgesics programs, conducted at the University of Queensland, Australia.
This funding will support and reinforce the Company's continued investments in its R&D programs.
The R&D tax incentive encourages companies to engage in R&D programs that have the potential to improve global health outcomes while generating economic benefits locally.
PreveCeutical's Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, "Receiving this tax credit, which provides us with funding without dilution of the Company's capital, has strengthened our financial position. We are very pleased with the results that we have got from our four programs in Australia. This funding will be applied towards the research and development programs and protection of our intellectual properties derived from these programs."
Your No. 5 Potential Catalyst For PRVCF
As of close on Tuesday, PRVCF was displaying multiple bullish technical indicators according to Barchart.
Here's a list of them to watch closely:
Short Term Indicators
- 20 - 100 Day MACD Oscillator
- 20 - 200 Day MACD Oscillator
Medium Term Indicators
- 50 - 100 Day MACD Oscillator
- 50 - 150 Day MACD Oscillator
- 50 - 200 Day MACD Oscillator
Long Term Indicators
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - 200 Day MACD Oscillator
With so many triggered technical indicators, could PRVCF be ready for a major run?
It was less than 2 months ago on July 14th that PRVCF hit a high of $.10.
From PRVCF's Tuesday close of $.03, that gives this biotech profile upside potential of roughly 233%!
Now, I'm not saying that PRVCF is going to make a 200%+ run tomorrow to that previous $.10 high, but you need to be aware of this profile's upside potential.
Plus, with this company releasing so much positive news in recent weeks that I noted above, could PRVCF's next press release help kick off a big valuation surge in the short-term?
Coverage is officially initiated on PRVCF immediately.